Back to results
US 2023/0265138 A1Published application
Stabilized bcl9 peptides for treatment of aberrant wnt signaling
AssigneeWntRx Pharmaceuticals Inc.
InventorDavid Zhu
Life of this patent
Estimating the term…
Abstract
Methods for treating cancer with a stabilized BCL9 peptide are encompassed, wherein the stabilized peptide comprises a portion of the HD2 domain of the BCL9 protein containing a hydrocarbon crosslinker generated using α,α-disubstituted amino acids.
Claims11
(canceled)
A method of manufacturing a polypeptide having a length of 7-14 amino acids, wherein the polypeptide is derived from the HD2 domain of human B-cell CLL/lymphoma 9 (BCL9), the polypeptide is capable of undergoing a reaction to form a hydrocarbon crosslinker, and the polypeptide comprises any sequence selected from:
- (SEQ ID NO:
- 79)
- LQTLRXaa1IQRXaa2L;
- and
- (SEQ ID NO:
- 82)
- Xaa1LQXaa2LRXaa3IQRXaa4L
- and wherein:
- Xaa1, Xaa2, Xaa3, and Xaa3 are each an α-methyl, α-alkenyl amino acid;
- the method comprising using solid phase synthesis to generate the polypeptide.
7 more elements
Dependencies are inferred from the claim text.